Arformoterol
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Arformoterol".

Arformoterol
Systematic (IUPAC) name
N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide
Identifiers
CAS number	67346-49-0
ATC code	?
PubChem	?
DrugBank	DB01274
Chemical data
Formula	C19H24N2O4
Mol. mass	344.405 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	52–65%
Metabolism	?
Half life	26 hours
Excretion	?
Therapeutic considerations
Licence data	US
Pregnancy cat.	C(US)
Legal status	℞-only(US)
Routes	nebuliser

Arformoterol, also known as arformoterol tartrate (USAN) is a long acting beta-adrenoceptor agonist drug indicated for the treatment of COPD. It is sold by Sepracor, under the tradename Brovana, as a solution to be administered twice daily (morning and evening) by nebulization.^[1]

It is the active (R,R)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.

References

External links

• Brovana website

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.